| # |
Company Name
|
Industry Name
|
Latest Price (Rs.)
|
Price Change
Rs (%) |
Market Cap
|
Net Sales
(Rs. Cr.) |
Latest EPS
(Rs.) |
Net Profit
Margin % |
Latest
P/E |
Latest
P/BV |
|---|---|---|---|---|---|---|---|---|---|---|
| Dr. Reddys Labs. | Pharmaceuticals& Drugs | 1,154 |
-1 (-0.09%) |
Mid Cap | 33,700 | 38.6 | 11.44 | 29.9 | 2.5 | |
| Lupin | Pharmaceuticals& Drugs | 2,111 |
-24 (-1.12%) |
Mid Cap | 27,958 | 120.9 | 18.82 | 17.7 | 4.1 | |
| Zydus Lifesciences | Pharmaceuticals& Drugs | 1,121 |
-14 (-1.23%) |
Mid Cap | 27,148 | 45.2 | 16.54 | 25.1 | 4.2 | |
| Glenmark Pharma. | Pharmaceuticals& Drugs | 2,427 |
-31.8 (-1.29%) |
Mid Cap | 16,983 | 63.7 | 15.9 | 38.6 | 6.3 | |
| Aurobindo Pharma | Pharmaceuticals& Drugs | 1,653.3 |
26.3 (1.62%) |
Mid Cap | 11,172 | 45.1 | 20.59 | 36.1 | 4 | |
| Mankind Pharma | Pharmaceuticals& Drugs | 2,328.6 |
-16.45 (-0.7%) |
Mid Cap | 10,421 | 52.8 | 19.97 | 44.4 | 5.7 | |
| Alkem Laboratories | Pharmaceuticals& Drugs | 5,192 |
7 (0.14%) |
Mid Cap | 9,664 | 178.4 | 22.7 | 29.1 | 4.3 | |
| Ipca Laboratories | Pharmaceuticals& Drugs | 1,965.1 |
9.9 (0.51%) |
Mid Cap | 7,289 | 49 | 16.38 | 39.9 | 5.9 | |
| Abbott India | Pharmaceuticals& Drugs | 26,072 |
193.45 (0.75%) |
Mid Cap | 6,929 | 759.9 | 22.25 | 34.1 | 10.6 | |
| Laurus Labs | Pharmaceuticals& Drugs | 1,840 |
-32.15 (-1.72%) |
Mid Cap | 6,813 | 20.2 | 12.82 | 92.5 | 17.9 | |
| Ajanta Pharma | Pharmaceuticals& Drugs | 3,464.5 |
-56.8 (-1.61%) |
Mid Cap | 5,453 | 90.8 | 19.33 | 38.8 | 9.1 | |
| Glaxosmithkline Phar | Pharmaceuticals& Drugs | 2,958.6 |
23.25 (0.79%) |
Mid Cap | 3,822 | 63.1 | 25.36 | 46.6 | 19.7 | |
| Biocon | Pharmaceuticals& Drugs | 397.3 |
-4.75 (-1.18%) |
Mid Cap | 2,346 | 0.6 | 5.85 | 670.6 | 2.4 | |
| Anthem Biosciences | Pharmaceuticals& Drugs | 933.9 |
-15.65 (-1.65%) |
Mid Cap | 2,089 | 11.1 | 30.95 | 85.7 | 16.4 |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: